Janux Therapeutics reports deep B-cell depletion in Phase 1 trial of JANX011
JANX•Janux Therapeutics reported deep, sustained B-cell depletion after a single JANX011 injection in 25 healthy volunteers, with no serious adverse events. Patient trials are planned for immune thrombocytopenia in the first half of 2027 and rheumatoid arthritis in the second half.
1. Phase 1 results
Janux Therapeutics announced initial Phase 1 results for JANX011 in 25 healthy volunteers. A single injection produced deep, sustained B-cell depletion without step-up dosing and selectively activated the intended T-cell subset. No serious adverse events occurred; cytokine release syndrome was mild, and transient, asymptomatic liver enzyme elevations required no treatment.
2. Planned patient trials
Janux plans to begin patient trials for immune thrombocytopenia in the first half of 2027, followed by rheumatoid arthritis trials in the second half.
